Format

Send to

Choose Destination
Mol Cell Endocrinol. 2016 Jun 15;428:82-8. doi: 10.1016/j.mce.2016.03.023. Epub 2016 Mar 17.

IGF1-R inhibition and liposomal doxorubicin: Progress in preclinical evaluation for the treatment of adrenocortical carcinoma.

Author information

1
Endocrine Research Unit, Medizinische Klinik und Poliklinik IV, Klinikum der Ludwig-Maximilians-Universität München, Munich, Germany.
2
Institute of Pharmaceutical Sciences, Department of Pharmaceutical Technology and Biopharmacy, Albert Ludwig University Freiburg, Freiburg, Germany.
3
Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA.
4
Endocrine Research Unit, Medizinische Klinik und Poliklinik IV, Klinikum der Ludwig-Maximilians-Universität München, Munich, Germany. Electronic address: Constanze.Hantel@med.uni-muenchen.de.

Abstract

Adrenocortical carcinoma (ACC) is a tumor with poor prognosis and limited therapeutic options. Therefore, in addition to multi-chemotherapeutic regimens IGF-1 receptor (IGF-1R) targeting approaches have been evaluated including immunoliposomal (IL) preparations utilizing an IGF-1R inhibiting antibody. In the current study, we extended our experiments by long-term treatment regimens in the classical adrenocortical NCIH295R xenograft model as well as by short-term experiments in two novel xenograft models, which all displayed different levels of IGF-1R and IGF-2 expression. Interestingly, these experiments reveal sub-group dependent differences in therapeutic outcome, reflecting clinical observations and indicate, thus, that implementation of this panel of tumor models might be helpful for clinical translation of novel therapeutic regimens in the future.

KEYWORDS:

Adrenocortical carcinoma; Caelyx(®); Immunoliposomes; Liposomal doxorubicin; MUC-1; NCI-H295R; SJ-ACC3

PMID:
26994514
DOI:
10.1016/j.mce.2016.03.023
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center